About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, April 7th, 2017

The QualityStocks
Daily Stock List


Emergent Capital, Inc. (EMGC)

We are reporting on Emergent Capital, Inc. (EMGC), today, here at the QualityStocks Daily Newsletter.

Emergent Capital, Inc. is a specialty finance company with its corporate headquarters in Boca Raton, Florida. The Company invests in life settlements and is an international leader in the life settlements industry. Emergent Capital has decades of experience creating value via the secondary and tertiary markets for life insurance policies. Life settlements are an alternative asset class that can provide high uncorrelated returns.

Emergent Capital lists on the OTC Markets Group’s OTCQB. The Company established in 2006 as Imperial Holdings, LLC. Since 2011 it has been publicly traded. In 2015, shareholders voted to change the Company’s name to Emergent Capital, Inc.

The Company has access to a broad and proven network of life settlement brokers and third-party providers from whom it sources appealing and value-added policies. Fundamentally, Emergent Capital purchases individual policies and portfolios of life insurance policies. It manages these assets based on comprehensive actuarial and market data.

In addition, an Emergent Capital subsidiary can act as a life settlement provider in over 30 states where it is able to pursue multiple opportunities within the life settlement space. The Company’s objective is to produce a consistent flow of investment opportunities encompassing all aspects of the life settlements marketplace. These range from lending to outright purchases of portfolios, to tertiary trades, and also individual secondary market purchases.

In March, Emergent Capital announced its financial results for the three months and year ended December 31, 2016. For the three months ended December 31, 2016, the Company’s Total Income from Continuing Operations was $3.7 million versus $3.1 million for the same period the year prior.

Emergent Capital reported a Net Loss from Continuing Operations of $23.7 million, or $(0.84) per diluted share for the three-month period ended December 31, 2016, versus a net loss of $13.7 million, or $(0.49) per diluted share for the same period in 2015.

For the year ended December 31, 2016, Emergent’s Total Income from Continuing Operations was $1.1 million versus $46.9 million during the same period the year prior. It reported a Net Loss from Continuing Operations of $49.4 million, or $(1.79) per fully diluted share, for the year ended December 31, 2016 versus a net loss of $30.4 million, or $(1.22) per fully diluted share, for the same period in 2015.

Emergent Capital, Inc. (EMGC), closed Friday's trading session at $0.28, down 8.65%, on 18,578 volume with 9 trades. The average volume for the last 60 days is 124,458 and the stock's 52-week low/high is $0.2012/$0.35.

MEDITE Cancer Diagnostics, Inc. (MDIT)

Wall Street Mover reported earlier on MEDITE Cancer Diagnostics, Inc. (MDIT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MEDITE Cancer Diagnostics, Inc. is a medical technology company listed on the OTC Markets Group’s OTCQB. The Company specializes in the development, engineering, manufacturing, and marketing of premium medical devices and consumables. These are for detection, risk assessment, as well as diagnosis of cancer and related disease.

MEDITE Cancer Diagnostics is based in Orlando, Florida. MEDITE is a Delaware registered company consisting of wholly-owned MEDITE GmbH a Germany-headquartered company with its subsidiaries. The Company previously went by the name CytoCore, Inc. It changed its name to MEDITE Cancer Diagnostics, Inc. in December of 2014.

MEDITE’s sole emphasis is on inventive solutions for cancer diagnostics. It is a foremost developer and manufacturer of unique, high-quality equipment and supplies for histology, pathology, and cytology laboratories. The Company is also engaged in the design, development, and commercialization of cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer.

MEDITE has a presence in 70 worldwide markets. It has a complete range of Histology and Cytology lab equipment and supplies. The Company’s focus is on attractive market-and product segments characterized by one or two players. Therefore, there is room for Company market share growth.

MEDITE offers USE33, an ultrasonic decalcification instrument, which automatically runs the process under controlled temperatures; TPC15 Duo or Trio; TES99; TES Valida; M530; A550; M380; TST44; COT20 linear staining systems; and RCM9000, ACS720, and TWISTER glass and robotic coverslippers.

Furthermore, MEDITE provides the SoftPAP device for the collection of cervical cell samples used in the detection of cervical dysplasia, cancer, and human papillomavirus infections. The Company also develops the SoftKit device for the self-collection of a sample that can undergo evaluation to provide an assessment of the health of the entire female genital tract; BreastPap breast cancer risk assessment devices; and SureThin and SafePrep products.

Recently, MEDITE Cancer Diagnostics announced that Mr. Eric M. Goehausen was elected to MEDITE's Board of Directors. Mr. Goehausen has over 17 years of corporate advisory, Chief Financial Officer (CFO), and executive-level financial management responsibilities.

Since 2003, he has been the managing member of New Harbor Merchant Partners. New Harbor is a private family investment office that invests in growth-oriented businesses and special situations. At present, Mr. Goehausen also serves as the Director of Revenue Growth of the Clinical Solutions Team of Anthem, Inc., which is a Fortune 30 company.

MEDITE Cancer Diagnostics, Inc. (MDIT), closed Friday's trading session at $0.8042, even for the day, on 5 volume with 1 trade. The average volume for the last 60 days is 3,300 and the stock's 52-week low/high is $0.26/$0.8949.

Abattis Bioceuticals Corp. (ATTBF)

CFN Media Group, Goldman Small Cap Research, Promotion Stock Secrets, Stockgoodies, InvestorIntel, Cannabis Financial Network News, Greenbackers, PennyStocks24, and Information Solutions Group reported earlier on Abattis Bioceuticals Corp. (ATTBF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Abattis Bioceuticals Corp. is a specialty, vertically-integrated biotechnology company. It aggregates, incubates, integrates, and invests in the botanical drug development industry. The Company’s divisions include Biocell Labs, Inc. and Vergence Sales & Marketing, Inc. Through these, it develops and licenses natural health products. Also, its other divisions are Northern Vine Canada, Inc.; North American Bioextracts, Inc.; and Biocube Green Grow Systems Corp. Abattis Bioceuticals is based in Vancouver, British Columbia.

The Company has made investments in companies such as Phytalytics (51 percent), IPS (51 percent) and Experion (25 percent). As a result, Abattis has capabilities, which support the production and extraction of botanical ingredients for its products; one of which includes cannabis.

Abattis develops and licenses natural health products, medicines, extractions, and ingredients - some of which will contain cannabinoid compounds.  These are for the biologics, nutraceutical, bioceutical, and cosmetic markets. Also, the Company has an extensive pipeline of high-quality products and intellectual property (IP) for the fast-growing botanical drug market.

Abattis Bioceuticals’ products and services include Botanical Blends & Formulas; CBD Ingredients; Functional Foods & Beverages; Research and Development (R&D); Analytical Services; and Pharma & Nutraceuticals. Abattis has received a Natural Product Number (NPN) approval for Phyto(NOS). This NPN allows it to manufacture and sell Phyto(NOS) in Canada. Ingredient Identity of Santa Ana, California, completed the claim substantiation report required for the sale of Phyto(NOS)™ in the U.S.

Phyto(NOS) has applications in a wide variety of food, beverage, and nutraceutical products. Phyto(NOS) is an all-natural, patent-pending formulation. It naturally supports nitric oxide (a vasodilator) levels in the blood stream, supports nitric oxide production, and provides antioxidants.

Abattis Bioceuticals and Northern Vine entered into a Binding Memorandum of Agreement with Experion Biotechnologies to acquire up to 100 percent of Experion Biotechnologies, Inc. Abattis Bioceuticals and its subsidiary Northern Vine Canada, Inc., expect to advance up to $5 million in the near term and $2.5 million in deferred capital to implement lab expansion and increase Abattis' proportionate share of Experion Biotechnologies. Abattis Management has been concentrating their efforts on its Northern Vine Lab buildout after receiving their controlled substance dealers license (CSL) last year. Northern Vine Labs has the required licenses and controls in place to legally possess and work with the raw herb (cannabis) and its active ingredients.

Northern Vine will provide analytical R&D and quality control testing on a huge array of cannabis based products, screening for cannabinoids, terpenes, microbiological contaminants, pesticides and residual solvents. The license also allows it to formulate new products for licensed producers in Canada.

Yesterday, Abattis Bioceuticals announced it has officially been added to The Marijuana Index, within the Biotechnology sector. The North American Marijuana Index tracks the leading public cannabis companies operating in the U.S. and Canada.

Abattis Bioceuticals Corp. (ATTBF), closed Friday's trading session at $0.21, up 12.30%, on 4,027,564 volume with 756 trades. The average volume for the last 60 days is 900,139 and the stock's 52-week low/high is $0.015/$1.00.

Airborne Wireless Network (ABWN)

Profitable Trader Authority, Damn Good Penny Picks, Penny Picks, Epic Stock Picks, Beacon Equity Research, Broad Street, OTCBB Journal, Stock Preacher, StocksImpossible, Penny Stock 101, PennyStockLocks, StockRockandRoll, InvestorSoup, Penny Stock Craze, Penny Stocks Finder, Stock Commander, and SuperStockTips reported on Airborne Wireless Network (ABWN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Airborne Wireless Network’s plan is to be a high-speed broadband internet pipeline to improve coverage connectivity now lacking. The Company’s intention is to create a high-speed broadband airborne wireless network through linking commercial aircraft in flight. Each aircraft participating in the network will act as an airborne repeater or router, sending and receiving broadband signals from one aircraft to the next. This will create a digital superhighway in the sky. OTCQB-listed, Airborne Wireless Network is based in Simi Valley, California.

Concerning its Wholesale Carrier Network, the Company’s plan is to utilize commercial aircraft as “mini-satellites”. Airborne Wireless Network’s principal target customer-base will be global data and communications service providers. Its system is to operate in a safe and controlled environment, typically between 20,000 and 40,000 feet (6,000-12,000 m).

The Company is developing a fully meshed network. In a fully meshed network, signals come in from multiple directions. The system will route signals around any obstructions. In essence, it is a virtual airborne Worldwide Web. Because it is a meshed network, it is similar to a web where all nodes are connected through numerous links.

Airborne Wireless Network does not intend to provide retail customer coverage to end users. It will act as a wholesale carrier with target customers. Airborne believes that its network, upon development, should provide low cost, high-speed connectivity to rural areas, island nations, ships at sea, oil platforms, plus connectivity to commercial and private aircraft in flight.

Airborne Wireless Network has completed its acquisition of Patent Number US 6,285,878 B1 and the Trademark "Infinitus Super Highway". These acquired assets serve as a blueprint and road map for it to develop its "Airborne Wireless Network". In November 2016, Airborne Wireless Network announced it received an FAA Project Number for its Supplemental Type Certificate (STC) application to install a Broadband Transceiver System on Boeing 757-200 aircraft.

Airborne Wireless Network considers receiving this project number as a major milestone; it’s the first STC application for its contemplated broadband wireless network, trademarked as the aforementioned “Infinitus Super Highway."  This STC is the first of its type filed for certification with the FAA.  Airborne Wireless Network owns this STC and its system description in its entirety. This includes hardware and software.

Last week, Airborne Wireless Network announced it filed for an experimental Federal Communication Commission (FCC) license file number 0378-EX-ST-2017 to commence air-to-air and air-to-ground meshed network system evaluations. Upon approval, this license will permit the Company to start ground and flight radio frequency transmission testing of its patented technology, the Infinitus Super Highway™.

The demonstration system has been lab tested at one of Airborne Wireless Network's contracted partner facilities. It will now take these successful results and bring them to its test bed Boeing 757 aircraft for ground fitting, testing on the tarmac, and eventual flight evaluation.

Airborne Wireless Network (ABWN), closed Friday's trading session at $3.05, up 0.99%, on 72,104 volume with 131 trades. The average volume for the last 60 days is 323,188 and the stock's 52-week low/high is $0.25/$4.07.

BioCorRx, Inc. (BICX)

Equity Observer, SmallCapVoice, Value Penny Stocks, MassiveStockProfits, BUYINS.NET, OTPicks, Damn Good Penny Picks, Penny Stock Newsletter, PREPUMP STOCKS, Penny Picks, and PennyStocks24 reported on BioCorRx, Inc. (BICX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

BioCorRx, Inc. is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. The Company offers an innovative approach to the treatment of substance abuse addiction and has its BioCorRx® Recovery Program. BioCorRx’s emphasis is on improving the quality of life for recovering addicts. The Company is headquartered in Anaheim, California.

The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program. The program consists of two primary components. The first component consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist, which can considerably decrease physical cravings for alcohol and opioids.

The second component is a one-on-one proprietary counseling program. It is specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. Furthermore, BioCorRx has expanded the support structure to include 12 months of a peer-support system employing trained recovery specialists. Also, the Company is developing a patent pending injectable form of naltrexone.

Furthermore, BioCorRx has a research and development (R&D) subsidiary, BioCorRx Pharmaceuticals. At present, this subsidiary is developing a new injectable naltrexone technology (BICX101) via a partnership with TheraKine Ltd. BioCorRx’s intention is to seek Food and Drug Administration (FDA) approval for BICX101 and/or its naltrexone implant product(s). BICX101 is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism.

In March, BioCorRx announced positive preliminary data from preclinical studies evaluating BICX101. So far in the preclinical studies, the product is successfully delivering above adequate sustained release levels of naltrexone. The study has so far confirmed several of the expected advantages of BICX101.

This week, BioCorRx announced that it received updated data from preclinical studies for BICX101. It announced that three different formulations were successful in reaching 28 days of sustained release of naltrexone.

Mr. Brady Granier, BioCorRx Chief Executive Officer, President, and Director, stated, "We are thrilled that we have been able to hit this milestone in vivo for the first time. Thanks to the work of our team and the folks at TheraKine and Covance, we are getting closer to a final product. We still need to fine tune the formulation to maximize performance, but this data is very exciting. Not only have we reached 28 days of release, but we did it with an injection volume of only 1 ml."

BioCorRx, Inc. (BICX), closed Friday's trading session at $0.2764, down 1.81%, on 2,983,609 volume with 539 trades. The average volume for the last 60 days is 439,795 and the stock's 52-week low/high is $0.01/$0.34.


The QualityStocks
Company Corner


GreenStone Healthcare Corp. (GRST)

The QualityStocks Daily Newsletter would like to spotlight GreenStone Healthcare Corp. (GRST). Today, GreenStone Healthcare Corp. closed trading at $0.0499, up 31.32%, on 15,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 64,824, and its 52-week low/high is $0.015/$0.083.

GreenStone Healthcare Corp. (GRST), through its subsidiaries, offers addiction and mental health rehabilitation treatments for residents, including out-patient counseling, coaching, intervention, psychological assessment, and other related services. The company recently sold its Canadian addiction treatment operations and acquired a U.S. based treatment center in Delray Beach, Florida, a major U.S. center for drug treatment programs located between Palm Beach and Miami. The company sought to expand into the U.S., where it could revolutionize treatment in that country with the skills it acquired in Canada. The company, through a subsidiary, will own and lease their assets in Canada, offering a stable secondary cash flow. Their newly acquired U.S. treatment center will be operated through a Florida limited liability company named Seastone Delray Healthcare LLC.

More than two thirds of families have been touched by a family member's addiction to alcohol, drugs, sex, and/or gambling. The addiction treatment market in the U.S. is estimated at over $35 billion annually, with a greater need than there are facilities. In addition, the GreeneStone approach differentiates itself in a number of ways:

  • Residents are treated holistically, taking into consideration all factors that can feed addiction, rather than the isolated treatment of addiction alone. Upon admission, all residents are fully assessed by professionals of a multidisciplinary team to develop an overall holistic treatment plan. An assembled team of best-in-class experts, including psychiatrists, physicians, nurses, and clinicians, manage and support residents who have co-occurring disorders such as depression, anxiety, and trauma.
  • Support is available both before and after resident treatment. Families can receive intervention support prior to admission, an often critical time for families and patients. Follow-up treatment support is available, to ensure progress and minimize the incidence of relapse. Families and others that are integral to the recovery are encouraged to participate in counseling and education sessions for continued success after in-patient treatment.

In addition to his experience with GreeneStone Healthcare, company president Shawn Leon has more than 25 years of experience managing public and private development-stage companies for various industries. He has provided financing and capital markets oversight for a number of these ventures, many of which have involved negotiations for mergers and acquisitions. Disclaimer

GreenStone Healthcare Corp. Company Blog

GreenStone Healthcare Corp. News:

GreeneStone Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida

GreeneStone Signs Definitive Agreement to Acquire Seastone of Delray, a Florida Limited Liability Company

GreeneStone Signs LOI to Acquire Aurora Recovery

National Waste Management Holdings, Inc. (NWMH)

The QualityStocks Daily Newsletter would like to spotlight National Waste Management Holdings, Inc. (NWMH). Today, National Waste Management Holdings, Inc. closed trading at $0.10, up 11.11%, on 36,872 volume with 5 trades. The stock’s average daily volume over the past 60 days is 18,515, and its 52-week low/high is $0.06/$0.46.

National Waste Management Holdings, Inc. (NWMH) is a solid waste management company offering comprehensive solutions for full waste diversion along Florida's west coast and in upstate New York. With an established base of long-term partnerships with municipal, institutional, commercial and industrial customers, along with a successful acquisition strategy, National Waste has set its course to become a leading waste diversion company.

National Waste's 54-acre landfill facility located in Hernando, Florida, handles annual average disposals of roughly 240,000 cubic yards of construction debris annually. The site also offers an array of ancillary services such as roll-off dumpster services, mulching services and recycling. While the landfill facility is already permitted for future expansion, National Waste's growth strategy also calls for the opening of new satellite offices in counties and states that neighbor its existing operations.

In addition to increasing its geographic foothold, National Waste employs a strategic acquisition model to increase its overall market share. In 2015, the company acquired Gateway Rolloff Services LP and Waste Recovery Enterprises LLC, which are expected to generate a combined $3.8 million in annual revenue for National Waste moving forward. In the second quarter of 2016, National Waste added Sivart Services to its roster, creating an immediate source of additional revenue and expanding its foothold in the northeast area of New York.

Management has confirmed its interest in additional acquisition targets while demonstrating its ability to effectively integrate and organically grow the company's existing acquisition companies and maintain efficient operations. Disclaimer

National Waste Management Holdings, Inc. Company Blog

National Waste Management Holdings, Inc. News:

National Waste Management Holdings, Inc. Expands Territory with Acquisition of Burts Refuse, LLC

National Waste Management Holdings, Inc. (NWMH) Expands Market Reach in New York with Acquisition of Northeast Data Destruction and Recycling

National Waste Management Holdings, Inc. Ends Year on High Note, Announces Final Acquisition of 2016

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.3201, up 2.29%, on 58,183 volume with 37 trades. The stock’s average daily volume over the past 60 days is 134,404 and its 52-week low/high is $0.05/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

NetworkNewsWire Announces Publication on Solutions for the Health Care Industry's Data Processing Needs

NetworkNewsWire Announces Publication of Discussion on the Value of IT & Big Data Analytics for the Health Care Industry

NetworkNewsWire Releases Exclusive Audio Interview with ORHub, Inc. (ORHB)

Monaker Group, Inc. (MKGI)

The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $2.82, up 0.71%, on 2,100 volume with 5 trades. The stock’s average daily volume over the past 60 days is 7,507, and its 52-week low/high is $1.33/$4.35.

Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.

NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.

Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.

Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.

In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.

With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.

Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer

Monaker Group, Inc. Company Blog

Monaker Group, Inc. News:

Monaker Group to Present at the 29th Annual ROTH Conference, March 15, 2017

Monaker Group Appoints Robert Post to Board of Directors

Monaker Group Appoints Simon Orange to Board of Directors Appointment Advances Monaker's Plans for NASDAQ Listing

MGX Minerals, Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals, Inc. (MGXMF). Today, MGX Minerals, Inc. closed trading at $0.8768, off by 1.81%, on 104,472 volume with 63 trades. The stock’s average daily volume over the past 60 days is 147,055, and its 52-week low/high is $0.11/$2.119.

MGX Minerals, Inc. (MGXMF) a diversified mining company based in Vancouver, holds asset portfolios in lithium, magnesium, and silicon in western Canada, with a stated focus on the development of industrial mineral portfolios in specific commodities and jurisdictions offering near-term production potential, minimal barriers to entry, and low initial capital expenditures. Targeting properties where large-scale development opportunities exist, they prefer to acquire regional control in mineral properties to enhance portfolio value, and engage industry experts to mitigate execution risk and improve time to market.

Positive developments have made the company's lithium operations a special point of interest. An important factor is the company's engineering partner Purlucid Treatment Solutions, which has developed technologies representing a major step in the process of extracting lithium from petroleum brine water (petrolithium). MGX already holds the largest lithium portfolio in Canada, with its Sturgeon Lake property in Alberta and other lithium assets, and the company is the sole proprietary technology holder for processing petrolithium. Purlucid has now successfully demonstrated a way to upgrade brine samples from 67mg/L of lithium to 1600mg/L of lithium, while at the same time removing all magnesium, boron, and potassium. This significant pre-processing achievement, generating solutions 1200 percent higher than anticipated, can be expected to have an impact on the cost of production for the entire petrolithium process, since, according to Purlucid CEO Dr. Preston McEachern, the "biggest challenge in lithium recovery is creating a clean brine."

MGX and Purlucid together are already in the bulk sample and pilot plant design optimization phase of development in preparation for deployment, progressing toward unlocking their calculated 2 million metric ton lithium carbonate resource. The initial petrolithium pilot plant is projected to process 12,000 liters of brine per day, and management now sees a future plant capable of handling over a million liters of brine per day. It can be reasonable that future plants will be located near a major operation's water collection and reinjection sites, complete with available infrastructure already in place. Using a current conservative price of $12,000 per metric ton, and the potential to produce upwards of 14,000 metric tons of lithium carbonate per year, the potential from just one major plant would be revenues of nearly $170 million annually.

Additionally, MGX Minerals holds the sole legal patent on the petrolithium process across North America, and is now planning operations in Utah, near the emerging Gigafactory underway by Tesla, with its anticipated demand for lithium. The company believes there is a virtually endless source of lithium-bearing brines in North America.

Supporting this is the company's operations with silicon and magnesium. MGX Minerals controls three high-grade silicon projects in British Columbia. There are currently no producers of silicon in western North America, and the company is evaluating the economic viability of producing silicon metal from high-purity quartzite. MGX is also now developing North America's next magnesium oxide mine in central British Columbia, a location with good mineralization and excellent infrastructure. Disclaimer

MGX Minerals, Inc. Company Blog

MGX Minerals, Inc. News:

NetworkNewsWire Announces Publication that Reviews the Global Lithium Market and Discusses Innovators Rising to Meet Demand

MGX Minerals Acquires 110,000 Acres of Paradox Basin, Utah Oil and Gas Leases

MGX Minerals Reports Advancement of Lithium Filtration Technology - 1600mg/L Li Concentrate from 67 mg/L Li Petro Lithium Brine


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(CCCR) +132.47%


(MAVT) +121.05%


MarketClub Analysis
(CETC) +101.73%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251